ClinicalTrials.gg
CompletedNCT03268343Updated Feb 26, 2019Results posted

A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine

A Phase 1 interventional study of Cytisine in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
19th of 22
24 · median 202
Started
2017
with 2 others
Phase 1
6 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 19th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 1, and was the 3rd registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

This will be an open-label, randomised, 2-period, single-dose crossover study to determine the comparative bioavailability of cytisine following single-dose administration in healthy male and female subjects under fed and fasted conditions.

The study will be comprised of a pre-study screen, followed by 2 treatment periods (1 and 2) and a post-study follow-up.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females between 18 and 55 years of age.

    1. If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of (unless of non- or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of medicinal product (IMP).
    2. If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.
    3. If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of IMP.
  2. Subject with a (BMI) of 18-32 kg/m\^2. BMI = body weight in kg / [height in m]\^2.
  3. Subject with no abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of IMP.
  4. Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of IMP (a positive alcohol or cotinine result may be repeated at Investigator's discretion).
  5. Subject with negative (HIV), surface antigen (Hep B) and virus antibody (Hep C) results.
  6. Subject with no clinically significant abnormalities in 12-lead determined after minimum of 5 minutes in supine position within 28 days before the first dose of IMP.
  7. Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-150 mmHg, diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40-110 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of IMP.
  8. Subject must be available to complete the study (including post study follow-up) and comply with study restrictions.
  9. Subject must provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Known /allergy reaction to varenicline, other cytisine-derivatives or any of the in the Tabex formulation (lactose, cellulose, talc, magnesium).
  2. History of severe hypersensitivity reactions to any other drugs.
  3. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).
  4. Difficulty in donating blood on either arm or known history.
  5. History of alcoholism or drug abuse within last 2 years.
  6. Regular nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum or electronic cigarettes) within previous 3 months and inability to refrain from nicotine intake from Screening until end of study.
  7. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of IMP, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
  8. Participated in any drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomization on Day 1 of Period 1.
  9. Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the first dose of IMP.
  10. Any special food restrictions that may hinder ability to consume the high fat breakfast provided during the study; such as lactose intolerance, vegan, low-fat, low sodium, etc.
  11. Any inability or difficulty in fasting.
  12. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).
  13. Any other condition that the Principal Investigator considers making the subject unsuitable for this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Schedule A: Fed Then Fasted

    Schedule A (12 subjects): * Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state). * Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).

    Drug: Cytisine

  • Experimental
    Schedule B: Fasted Then Fed

    Schedule B (12 subjects): * Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state). * Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).

    Drug: Cytisine

Interventions

  • Cytisine 1.5 mg Film-Coated Tablets

    Also known as: Tabex

06

What researchers measure

Primary outcomes

  1. Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  2. Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

Secondary outcomes

  1. Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  2. Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  3. Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  4. Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  5. Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)

    Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)

  6. Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae)

    Time frame: Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose

  7. Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)

    To assess the renal elimination of cytisine via measurement of urinary concentrations of cytisine.

    Time frame: Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to AEs, by Severity and Relationship

    An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with the treatment. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of study drug that worsen after the subject receives the first dose of study drug. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient's hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. Event severity was categorized as mild, moderate, or severe. Relationship of event to study drug was categorized as definite, probably, possible, unlikely, not related, or not applicable (N/A).

    Time frame: Day -1 to Day 7 plus 6-8 days (post-study follow-up)

07

Results

Posted Feb 7, 2019

Participant flow

Participant flow — Overall Study
Milestone3 mg Cytisine, Schedule A: Fed Then Fasted3 mg Cytisine, Schedule B: Fasted Then Fed
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryPlasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · ng/mL
Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
ng/mL3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)22.9 ± 5.4430.8 ± 7.91
Statistical analysis
  • 3 mg Cytisine, Fed vs 3 mg Cytisine, Fasted · Geometric ls mean ratio (%): 74.71 · 90% CI 66.39 to 84.08fed / fasted; results obtained using an ANOVA with fixed effects of treatment, period, sequence and participant (sequence).
PrimaryPlasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · h*ng/mL
Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)
h*ng/mL3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)170 ± 30.3176 ± 33.1
Statistical analysis
  • 3 mg Cytisine, Fed vs 3 mg Cytisine, Fasted · Geometric ls mean ratio (%): 97.04 · 90% CI 94.20 to 99.98fed / fasted; results obtained using an ANOVA with fixed effects of treatment, period, sequence and participant (sequence).
SecondaryPlasma Cytisine PK: Time of Occurrence of Cmax (Tmax)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Median · hours
Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax)
hours3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax)2.75 (0.500 to 6.12)0.75 (0.333 to 3.00)
Statistical analysis
  • 3 mg Cytisine, Fed vs 3 mg Cytisine, Fasted · Wilcoxon Signed-Rank test · p = < 0.0001 · Median difference (final values): 1.38 · 95% CI 0.50 to 2.25Hodges-Lehmann method
SecondaryPlasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · h*ng/mL
Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)
h*ng/mL3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)163 ± 29.4169 ± 33.0
Statistical analysis
  • 3 mg Cytisine, Fed vs 3 mg Cytisine, Fasted · Geometric ls mean ratio (%): 96.52 · 90% CI 93.30 to 99.85fed / fasted; results obtained using an ANOVA with fixed effects of treatment, period, sequence and participant (sequence).
SecondaryPlasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · percentage of extrapolated part
Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)
percentage of extrapolated part3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)4.37 ± 1.403.85 ± 1.46
SecondaryPlasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · 1/hour
Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)
1/hour3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)0.154 ± 0.03910.156 ± 0.0314
SecondaryPlasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)
Time frame:
Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Reported as:
Mean · hours
Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)
hours3 mg Cytisine, Fed3 mg Cytisine, Fasted
Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)4.77 ± 1.164.59 ± 0.832
SecondaryUrine Cytisine PK: Amount Excreted in Urine Over Time (Ae)
Time frame:
Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose
Reported as:
Mean · mg
Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae)
mg3 mg Cytisine, Fed3 mg Cytisine, Fasted
Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae)2.59 ± 0.4072.47 ± 0.357
Statistical analysis
  • 3 mg Cytisine, Fed vs 3 mg Cytisine, Fasted · Geometric ls mean ratio (%): 104.75 · 95% CI 98.97 to 110.87fed / fasted; results obtained using an ANOVA with fixed effects of treatment, period, sequence and participant (sequence).
SecondaryUrine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)

To assess the renal elimination of cytisine via measurement of urinary concentrations of cytisine.

Time frame:
Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose
Reported as:
Mean · percentage of drug excreted
Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)
percentage of drug excreted3 mg Cytisine, Fed3 mg Cytisine, Fasted
Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)86.5 ± 13.682.4 ± 11.9
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to AEs, by Severity and Relationship

An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with the treatment. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of study drug that worsen after the subject receives the first dose of study drug. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient's hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. Event severity was categorized as mild, moderate, or severe. Relationship of event to study drug was categorized as definite, probably, possible, unlikely, not related, or not applicable (N/A).

Time frame:
Day -1 to Day 7 plus 6-8 days (post-study follow-up)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to AEs, by Severity and Relationship
participants3 mg Cytisine, Fed3 mg Cytisine, Fasted
≥ 1 TEAE67
≥ 1 Serious TEAE00
≥ 1 TEAE Leading to Withdrawal of Study Drug00
≥ 1 Mild TEAE67
≥ 1 Moderate TEAE00
≥ 1 Severe TEAE00
≥ 1 TEAE Definitely Related to Study Drug00
≥ 1 TEAE Probably Related to Study Drug11
≥ 1 TEAE Possibly Related to Study Drug35
≥ 1 TEAE Unlikely Related to Study Drug11
≥ 1 TEAE Not Related to Study Drug00
≥ 1 TEAE Relationship to Study Drug = N/A10

Adverse events

Collected over Day -1 to Day 7 plus 6-8 days (post-study follow-up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mg Cytisine, Fed0/24 (0%)0/24 (0%)6/24 (25%)
3 mg Cytisine, Fasted0/24 (0%)0/24 (0%)7/24 (29.2%)
3 mg Cytisine, Overall0/24 (0%)0/24 (0%)10/24 (41.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
Event3 mg Cytisine, Fed3 mg Cytisine, Fasted3 mg Cytisine, Overall
DizzinessNervous system disorders2/243/244/24
VomitingGastrointestinal disorders2/241/243/24
HeadacheNervous system disorders2/242/243/24
NauseaGastrointestinal disorders1/241/242/24
Abdominal pain lowerGastrointestinal disorders0/241/241/24
Feeling hotGeneral disorders0/241/241/24
RhinitisInfections and infestations1/240/241/24
HypoaesthesiaNervous system disorders1/240/241/24
SomnolenceNervous system disorders0/241/241/24
Cold sweatSkin and subcutaneous tissue disorders1/240/241/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)3 mg Cytisine
Mean35.1 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)3 mg Cytisine
Female13
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)3 mg Cytisine
Caucasian23
Other, Not Specified1
08

Study locations

1 site
  • Simbec Research Ltd
    Merthyr Tydfil, CF11 9AB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2017, 0 months.

Results were first posted in Feb 2019, 1 year 5 months after primary completion.

Of 34 phase 1 interventional studies under Smoking Cessation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2017
First posted
Aug 31, 2017
StartActual
Aug 8, 2017
Primary completionActual
Aug 26, 2017
CompletionActual
Sep 1, 2017
Results first posted
Feb 7, 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03268343
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Aug 8, 2017
Primary completion
Aug 26, 2017
Completion
Sep 1, 2017
Results posted
Feb 7, 2019
Last update
Feb 26, 2019

Study contacts

Annelize Koch, MD
principal investigator · Simbec Research Ltd (Simbec)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion